Q-omics provides the consensus-scored C3P1 profile across patient tissues and cancer cell-line models. C3P1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C3P1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, C3P1 RNA expression shows 8,987 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LIHC, and ESCA as cancer lineages where C3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3P1 survival associations across molecular data types. C3P1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3P1 RNA expression–survival associations across cancer types. High C3P1 expression shows unfavorable associations in KIRC, ACC, KICH, KIRP and MESO, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C3P1 RNA expression.
This table summarizes C3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for C3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3P1 shows lower tumor expression in LIHC, KICH and CHOL and higher tumor expression in STAD, COAD and LUAD. The LIHC box plot shows higher C3P1 RNA expression in normal versus tumor tissue (log2 FC = −3.614, t-test p < 0.001).
This table shows molecular features associated with C3P1 in patient tissues and cancer cell lines. In patient samples, C3P1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C3P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
